# Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds

Source: https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/  
OnCo record `low-potassium-and-low-phosphate-on-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some cancer medicines lower the potassium or phosphate in the blood. A mild fall usually causes no symptoms, so it is found on blood tests and treated with tablets or a drip. The medicine is paused only when a low level is severe or does not respond. Tell your team about muscle weakness, cramps or pain, palpitations, or diarrhoea or vomiting. Your own team's plan comes first.

## Summary

Four medicines are covered from their own labels, US and EU side by side (dinutuximab in the US, dinutuximab beta in the EU); the general correction steps come from UK and society sources written for adults in general. Local protocols come first.

Quizartinib: the potassium rule is tied to the QT interval. Both labels ask for hypokalaemia and hypomagnesaemia to be monitored and corrected before and during treatment, more often with diarrhoea or vomiting. The US label alone contraindicates quizartinib in severe hypokalaemia and has a row for Grade 3 or 4 hypokalaemia (below 3 mmol/L): interrupt, correct according to institutional guidelines, and restart at the previous dose at Grade 2 or less without symptoms. The EU SmPC has neither; it reports two cardiac arrests, both in the setting of severe hypokalaemia. ECG and QTcF rules are on the QT protocol.

Nirogacestat: monitor phosphate and potassium regularly and supplement as necessary (both labels). Withhold, then restart at 100 mg twice daily once Grade 1 or less or baseline: in the US for Grade 3 or 4 hypophosphataemia persisting for 3 days or more despite maximal replacement, in the EU for Grade 3 persisting for 7 days or more; for hypokalaemia despite maximal replacement, Grades 3 or 4 in the US and Grade 3 of any duration in the EU.

Dinutuximab: the US label asks for serum electrolytes daily during therapy (severe hypokalaemia in 37% in its trial); the EU SmPC for dinutuximab beta recommends regular monitoring. Neither gives a potassium dose rule.

Abiraterone: correct hypokalaemia before and during treatment and check potassium at least monthly (US), or monthly and every 2 weeks for 3 months in people at significant risk of congestive heart failure (EU). Only the EU SmPC says to consider keeping potassium at 4.0 mM or above in people with hypokalaemia and to withhold for Grade 3 or higher.

Lutetium-177 dotatate is not covered: both labels list hypokalaemia and neither gives a rule for it. The one potassium rule, in the EU SmPC, concerns a high potassium from the amino acid infusion (see gaps).

Replacement: oral potassium for mild or moderate hypokalaemia and intravenous potassium chloride in hospital for severe or symptomatic hypokalaemia (NHS SPS, England); the 2014 SEOM guideline likewise gives potassium by mouth for mild and moderate and into a vein for severe hypokalaemia (level IV, grade D). The KDIGO conference participants think an ECG and magnesium should be checked. Sources differ on infusion rates. For phosphate there is no agreed guidance: the UK Q&A replaces below 0.3 mmol/L and considers it at 0.3 to 0.6 mmol/L, while a nephrology review says to correct low phosphate in people with cancer when it is first recognised.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: hypokalaemia on cancer treatment; hypokalemia; hypophosphataemia on cancer treatment; hypophosphatemia; low potassium on abiraterone; low phosphate on nirogacestat; potassium on quizartinib; electrolytes on dinutuximab; potassium replacement; phosphate replacement

## Connected records

- protocols: [Blood count, kidney and liver monitoring during lutetium-177 radioligand therapy](https://onco.cc/protocols/blood-count-and-kidney-monitoring-during-radioligand-therapy/), [Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment](https://onco.cc/protocols/capillary-leak-syndrome-on-anticancer-drugs/), [Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit](https://onco.cc/protocols/treatment-induced-diarrhoea-grading-and-management/), [High phosphate on FGFR inhibitors (erdafitinib, pemigatinib, futibatinib): monitoring, diet, binders and dose rules](https://onco.cc/protocols/hyperphosphataemia-on-fgfr-inhibitors/), [Hyponatraemia and SIADH in cancer: emergency hypertonic saline, safe correction and treating the cause](https://onco.cc/protocols/hyponatraemia-siadh/), [Ifosfamide: bladder protection with mesna and fluids, and ifosfamide encephalopathy](https://onco.cc/protocols/ifosfamide-bladder-protection-and-encephalopathy/), [Low magnesium on cetuximab and panitumumab: monitoring and replacement](https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/), [QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop](https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/), [Tumour lysis syndrome: risk assessment, prophylaxis and treatment](https://onco.cc/protocols/tumour-lysis-syndrome-prevention-and-treatment/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Dinutuximab (ch14.18) / dinutuximab beta](https://onco.cc/drugs/dinutuximab/), [Nirogacestat](https://onco.cc/drugs/nirogacestat/), [Quizartinib](https://onco.cc/drugs/quizartinib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [QT prolongation](https://onco.cc/terms/qt-prolongation/)

---
JSON: https://onco.cc/api/v1/entities/low-potassium-and-low-phosphate-on-anticancer-drugs.json